HEALWELL AI (AIDX) AI Stock Analysis

• Market Cap: C$398.98M
• Dividend Yield: N/A
• Average Volume (3M): 336.40K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.30
• Revenue Growth: 468.64%
• EPS Growth: 8.03%
• Country: CA
• Employees: 350
• Sector: Healthcare
• Sector Strength: 47
• Industry: Healthcare Providers & Services
• EPS (TTM): -0.02
• Shares Outstanding: 276,108,500
• 10 Day Avg. Volume: 514,171
• 30 Day Avg. Volume: 336,403
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$4.43
• Price Target Upside: 238.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 41 Neutral
• Price Target: C$1.50 ▲(14.50% Upside)

HEALWELL AI's overall stock score is primarily impacted by its strong revenue growth, which is overshadowed by significant profitability and cash flow challenges. The technical analysis indicates a bearish trend, and the negative P/E ratio highlights valuation concerns. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Acquisitions

The transformational acquisition of two segments of Orion Health and partnership with WELL Health Technologies are expected to enhance financial performance.

Profitability

Management maintained its key outlook for positive adjusted EBITDA in 2025 and 100% year-over-year growth in the AI and Data Science segment.

Revenue Growth

HEALWELL AI reported a revenue increase of 208% year-over-year, surpassing both estimates and consensus.

Negative Factors

Financial Performance

Adjusted EBITDA loss of (C$5.6M) was wider than estimates and consensus.

Revenue Expectations

Revenue is expected to be softer in the first half of the year due to a cutback on early-stage trials.

Stock Dilution

The primary reason for the lower price target is due to factoring in a higher share count.

HEALWELL AI Business Overview & Revenue Model

Company Description

Healwell AI Inc., a healthcare technology company, focuses on AI and data science for preventative care. It offers AI-enabled decision support platform for healthcare providers. Healwell AI Inc. has a strategic alliance agreement with WELL Health Technologies Corp to enhance the growth and development of AI-enabled healthcare technologies. The company was formerly known as MCI Onehealth Technologies Inc. and changed its name to Healwell AI Inc. in October 2023. Healwell AI Inc. was incorporated in 2012 and is headquartered in Toronto, Canada.

How the Company Makes Money

MCI Onehealth Technologies, Inc. generates revenue primarily through its suite of digital health solutions and services. The company earns income by providing telemedicine services, which include virtual consultations and remote patient monitoring. Additionally, it monetizes its data-driven insights and analytics by offering these services to healthcare providers and institutions looking to improve their operational efficiency and patient care. MCI Onehealth may also engage in partnerships with healthcare organizations, insurers, and technology companies to expand its reach and enhance its offerings, further contributing to its revenue streams.

HEALWELL AI Financial Statement Overview

Summary

MCI Onehealth Technologies demonstrates strong revenue growth, yet struggles with profitability and cash flow management. Despite increasing assets and equity, the company faces challenges in achieving sustainable operations due to persistent losses and negative cash flows. The financial stability is bolstered by financing activities, but operational improvements are necessary for long-term success.

Income Statement

The company has shown significant revenue growth from 2023 to 2024, but this growth has not translated into profitability. The gross profit margin is reasonable, but net income remains negative, indicating ongoing challenges in managing expenses relative to revenue. EBIT and EBITDA margins are also negative, which highlights operational inefficiencies.

Balance Sheet

The debt-to-equity ratio shows a moderate level of leverage, but the company has been able to maintain a positive equity ratio. Return on equity is negative due to continued net losses, which is concerning for long-term financial health. The balance sheet reflects an increase in total assets and equity, indicating some stability.

Cash Flow

The company is experiencing negative operating cash flow and free cash flow, which is worrisome. However, there has been a significant increase in financing cash flow, which may support operations temporarily. The free cash flow to net income ratio is unfavorable, indicating that the company is not generating cash efficiently.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.97M	7.32M	10.42M	47.82M	38.57M
Gross Profit	17.32M	1.26M	3.71M	15.01M	64.22M
EBITDA	-18.42M	-16.11M	-13.94M	-11.44M	2.11M
Net Income	-26.29M	-31.60M	-21.09M	-15.67M	-1.03M
Balance Sheet
Total Assets	125.53M	53.70M	45.63M	60.89M	22.36M
Cash, Cash Equivalents and Short-Term Investments	9.68M	19.16M	1.80M	7.68M	1.27M
Total Debt	22.20M	20.93M	17.42M	14.35M	15.04M
Total Liabilities	51.86M	32.23M	32.13M	31.14M	22.12M
Stockholders Equity	63.89M	12.65M	11.78M	28.03M	114.00K
Cash Flow
Free Cash Flow	-23.93M	-10.86M	-9.49M	-9.47M	3.99M
Operating Cash Flow	-22.62M	-10.80M	-8.35M	-7.10M	4.22M
Investing Cash Flow	-15.37M	1.35M	-1.17M	-8.64M	-234.00K
Financing Cash Flow	28.24M	27.20M	3.78M	21.99M	-4.22M

HEALWELL AI Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIDX, the sentiment is Negative. The current price of 1.31 is below the 20-day moving average (MA) of 1.37, below the 50-day MA of 1.37, and below the 200-day MA of 1.55, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.86 is Neutral, neither overbought nor oversold. The STOCH value of 15.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AIDX.

HEALWELL AI Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
AIDX	41 Neutral	C$398.98M	―	-41.85%	―	468.64%	8.03%
RHT.H	―	C$41.56M	―		―	―	―
NPTH	―	C$16.37M	―	-3.69%	―	―	―
JUMP	―	C$4.92M	2.84	37.43%	―	―	―
CDX.H	―	C$6.74M	―		―	―	―
KOVO	―	C$7.08M	―		―	―	―

HEALWELL AI Corporate Events

HEALWELL AI Reports Record Revenue Growth and Strategic Shift to AI Solutions

HEALWELL AI Inc. reported record revenue growth of 645% in Q2-2025, reaching $40.5 million, largely driven by the acquisition of Orion Health. This acquisition has significantly bolstered HEALWELL’s healthcare software business, which saw a 1,064% year-over-year increase. The company achieved its first quarter of positive Adjusted EBITDA, marking a pivotal shift in its financial trajectory and validating its scalable AI-driven business model. HEALWELL is focusing on becoming a pure-play digital SaaS and services company, divesting its clinical research and patient services units to concentrate on AI and healthcare software innovation. The strategic move aims to enhance its market position, leveraging existing customer bases and contracts to facilitate the adoption of AI solutions in healthcare systems worldwide.

The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.

HEALWELL AI to Release Q2 2025 Financial Results on August 13

HEALWELL AI announced it will release its Fiscal Second Quarter 2025 financial results on August 13, 2025, followed by a conference call and webcast to discuss the results. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.

HEALWELL AI Inc. Reports Strong AI Segment Growth and Acquires Full Ownership of Pentavere

HEALWELL AI Inc. announced significant improvements in its AI business segment, with revenues expected to exceed $5 million in the first half of 2025, marking a 200% year-over-year increase. The company has acquired full ownership of Pentavere Research Group Inc., enhancing its integration and commercialization efforts of AI products in healthcare, positioning itself as a leader in AI-driven preventative care.

The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on MCI Onehealth Technologies, Inc. Class A stock, see the TSE:AIDX Stock Forecast page.

HEALWELL AI Reports Strong Shareholder Support at 2025 AGM

HEALWELL AI announced the successful voting results from its 2025 annual general meeting, where shareholders representing approximately 71% of the votes attended. All business matters, including fixing the number of directors at six, re-electing the incumbent directors, and appointing Deloitte LLP as the new auditor, were approved, indicating strong shareholder support and continuity in the company’s governance.

The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on MCI Onehealth Technologies, Inc. Class A stock, see the TSE:AIDX Stock Forecast page.

HEALWELL AI Expands into U.S. Market with Orion Health Partnership

HEALWELL AI Inc. has announced its strategic expansion into the U.S. healthcare market by launching a suite of AI-enabled tools in collaboration with Orion Health’s established software offerings. This move is expected to enhance HEALWELL’s market presence by combining Orion Health’s extensive U.S. experience and infrastructure with HEALWELL’s AI capabilities, aiming to improve clinical outcomes and reduce administrative burdens. The expansion will focus on value-based care and population health initiatives, supported by a modular, FHIR-native repository to facilitate interoperability and real-time data sharing. HEALWELL plans to deepen its U.S. presence through strategic partnerships and acquisitions, positioning itself to support clinical research and development in the life sciences sector.

The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on MCI Onehealth Technologies, Inc. Class A stock, see the TSE:AIDX Stock Forecast page.